β-Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study

Germán Cediel, Xavier Carrillo, Cosme García-García, Ferran Rueda, Teresa Oliveras, Carlos Labata, Jordi Serra, Marc Ferrer, Oriol de Diego, Antoni Bayés-Genís

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

© 2018 Elsevier B.V. Background: The use of β-blocker therapy in the setting of acute coronary syndrome (ACS) associated with cocaine consumption (ACS-ACC) is discouraged due to the risk of coronary vasoconstriction. We examined the prognostic value of β-blocker therapy in a contemporary ACS cohort. Methods and results: Prospective, single-center study conducted between January 2001 and December 2014 that examined cocaine use among young (≤50-year-old) consecutive patients admitted with an ACS. During the study period, 1002 patients were admitted; of these, 57 (5.7%) had a positive cocaine urine test We collected data on clinical characteristics and major adverse cardiovascular events (MACE) during follow-up. Among ACS-ACC patients, 33 (57.9%) received β-blocker therapy during hospital admission and after discharge. During a median follow-up of 4.0 (IQR: 2.4–6.5) years after the index event, 2 (6.1%) patients treated with β-blocker therapy died and 6 (18.2%) experienced hospital re-admission for myocardial infarction (MI); in contrast, there were 5 (20.8%) deaths and 5 (20.8%) readmissions due to MI in patients without β-blocker therapy. Lower rates of MACE were observed in patients treated with β-blocker therapy (30.3%) than those without β-blocker therapy (41.7%). The 90-day survival was higher in patients treated with β-blocker therapy (87.5% vs. 100%; Log rank test p = 0.035). Conclusions: In patients with ACS-ACC, β-blocker treatment was associated with a significantly better clinical outcome, with lower rates of death and MI. Our findings support the evidence for long-term β-blocker administration in high-risk patients and highlight the need for large prospective multicenter studies of β-blocker treatment in ACS-ACC.
Original languageEnglish
Pages (from-to)7-10
JournalInternational Journal of Cardiology
Volume260
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Acute coronary syndrome
  • Cocaine
  • Prognosis
  • β-Blocker

Fingerprint Dive into the research topics of 'β-Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study'. Together they form a unique fingerprint.

  • Cite this

    Cediel, G., Carrillo, X., García-García, C., Rueda, F., Oliveras, T., Labata, C., Serra, J., Ferrer, M., de Diego, O., & Bayés-Genís, A. (2018). β-Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study. International Journal of Cardiology, 260, 7-10. https://doi.org/10.1016/j.ijcard.2018.02.013